Combining Two Immunotherapeutics for Asbestos-related Cancer
The FDA approved a combination of two immune checkpoint inhibitors to treat adult patients with unresectable malignant pleural mesothelioma.
Progress Against Cancer
The FDA approved a combination of two immune checkpoint inhibitors to treat adult patients with unresectable malignant pleural mesothelioma.
The FDA approved the first liquid biopsy companion diagnostic that uses next-generation sequencing to test for EGFR gene mutations in certain types of lung cancer.
The FDA has approved the first targeted therapeutic against B-cell maturation antigen (BCMA) to treat certain patients with multiple myeloma.
The FDA has approved a new immunotherapeutic for treating certain adult patients with diffuse large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) granted accelerated approval to a new targeted immunotherapeutic called tafasitamab-cxix...
The FDA has approved a combination of the immune checkpoint inhibitor atezolizumab with two targeted therapies for certain patients with advanced melanoma.
The FDA has approved a CAR T-cell immunotherapy to treat certain adult patients with mantle cell lymphoma.
The FDA approved an oral combination of an epigenetic therapy along with an enzyme inhibitor to treat certain adults with chronic myelomonocytic leukemia
The FDA approved the use of an immune checkpoint inhibitor as a first-line treatment for patients with colorectal cancers caused by genetic mutations that stem from an inability to repair mistakes or damage in DNA coding.
The FDA approved the use of an immune checkpoint inhibitor to treat certain patients with cutaneous squamous cell carcinoma.
The FDA has approved a targeted therapy drug to treat certain adult patients with diffuse large B-cell lymphoma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More